Objective
to evaluate the 12-month patency of the Eluvia DES (polymer-coated paclitaxeleluting stent) compared with BMS for the treatment of femoropopliteal lesions
Study
prospective, multicentre, randomised trial
Population
patients with symptomatic peripheral artery disease of the native superficial femoral artery or proximal popliteal artery
Endpoints
primary patency at 12 months defined as duplex ultrasound peak systolic velocity ratio ⩽ 2:4 in the absence of TLR or surgical bypass of target lesion
Conclusion
the 12-month primary patency after treatment of femoropopliteal lesions with DES was significantly higher compared to treatment with BMS
Gouëffic et al Circulation: 2022; 146:1564-76
